GPC3 and hepatocellular carcinoma: The 21 best performing TAAs selected for closer analysis included TAAs previously identified as promising leads in HCC such as IMP-1, KOC, p53 and c-myc [27], Sui1 and RalA [28], Calreticulin [37], and HCC1 [38] together with novel proteins such as Gankyrin and FASN, and well-known liver biomarkers such as AFP, GPC-3 and GRP78.